Sac-TMT for Active TNBC Brain Metastases
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a new drug called sacituzumab tirumotecan (Sac-TMT) for people with triple-negative breast cancer that has spread to the brain. It aims to see if the drug can shrink or control brain tumors without needing immediate radiation or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have triple-negative breast cancer that has spread to the brain, either newly found or growing after earlier treatments like radiation or surgery.
- You should have had at least one prior treatment with an antibody-drug conjugate (a type of targeted therapy).
- You must be able to care for yourself (ECOG performance status 0-1) and have a life expectancy of at least 3 months.
- You need adequate kidney, liver, and bone marrow function, as checked by blood tests.
- You cannot have had sacituzumab tirumotecan before, or have a known allergy to it, and must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) for people with a specific type of non-small cell lung cancer that has spread to the brain and has stopped responding to a certain targeted therapy. The goal is to see if this combination can shrink brain tumors and improve outcomes.
This study tests a new drug called sacituzumab tirumotecan (Sac-TMT) combined with radiation to the brain for people with EGFR-mutant lung cancer that has spread to the brain and has grown despite first-line EGFR inhibitor therapy. The goal is to see if this combination can control the brain tumors better.
Hear when a new Metastatic Triple Negative Breast Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.